Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer
- PMID: 33758160
- PMCID: PMC8006563
- DOI: 10.12659/MSM.929558
Genome-Scale Analysis Identified NID2, SPARC, and MFAP2 as Prognosis Markers of Overall Survival in Gastric Cancer
Abstract
BACKGROUND Gastric cancer is the most common gastrointestinal tumor, and the rates of recurrence and metastasis are high. Research results on molecular biomarkers used for prognosis of gastric cancer remain inconclusive. This study aimed to explore the gene expression module of gastric cancer and to determine potential prognostic biomarkers. MATERIAL AND METHODS Three microarray datasets (GSE13911, GSE79973, and GSE29272) from Gene Expression Omnibus (GEO), including 206 pairs of gastric tumors and adjacent normal samples, were used for analysis of differentially expressed genes (DEGs). The 3 microarray datasets yielded 144 genes associated with the progression and prognosis of gastric cancer. After this, a risk score model was developed for result validation using an independent dataset from The Cancer Genome Atlas. RESULTS The validation of the independent dataset showed significantly increased NID2, SPARC, and MFAP2 expression in gastric tumor tissues, which were associated with poor outcomes in gastric cancer patients. Moreover, the high risk score obtained was associated with poor overall survival (HR: 1.787; 1.069-2.986; P=0.027). Subgroup analyses revealed that these significant prognostic values were detected in patients aged <65.0 years, tumors in the antrum/distal colon, grade 3 tumors, or TNM-M0 stages of cancer. CONCLUSIONS The findings of this study show that NID2, SPARC, and MFAP2 are upregulated in gastric tumor tissues and are significantly associated with poor overall survival. Therefore, the predictive values of the risk score model employed for the prognosis of gastric cancer could be improved by using these 3 upregulated DEGs.
Conflict of interest statement
None.
Figures
Similar articles
-
FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics.Sci Rep. 2019 May 24;9(1):7827. doi: 10.1038/s41598-019-43924-x. Sci Rep. 2019. PMID: 31127138 Free PMC article.
-
NID2 can serve as a potential prognosis prediction biomarker and promotes the invasion and migration of gastric cancer.Pathol Res Pract. 2019 Oct;215(10):152553. doi: 10.1016/j.prp.2019.152553. Epub 2019 Jul 23. Pathol Res Pract. 2019. PMID: 31362888
-
Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients.Int J Oncol. 2020 Feb;56(2):460-469. doi: 10.3892/ijo.2019.4944. Epub 2019 Dec 16. Int J Oncol. 2020. PMID: 31894266 Free PMC article.
-
Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice?Can J Surg. 2012 Apr;55(2):117-24. doi: 10.1503/cjs.002310. Can J Surg. 2012. PMID: 22564515 Free PMC article. Review.
-
Prognostic Significance of SPARC Expression in Breast Cancer: A Meta-Analysis and Bioinformatics Analysis.Biomed Res Int. 2022 Feb 15;2022:8600419. doi: 10.1155/2022/8600419. eCollection 2022. Biomed Res Int. 2022. PMID: 35211625 Free PMC article. Review.
Cited by
-
Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer.World J Clin Cases. 2023 Jul 16;11(20):4763-4787. doi: 10.12998/wjcc.v11.i20.4763. World J Clin Cases. 2023. PMID: 37584004 Free PMC article.
-
SPARC: a potential target for functional nanomaterials and drugs.Front Mol Biosci. 2023 Jul 28;10:1235428. doi: 10.3389/fmolb.2023.1235428. eCollection 2023. Front Mol Biosci. 2023. PMID: 37577749 Free PMC article. Review.
-
Identification of Cancer Driver Genes by Integrating Multiomics Data with Graph Neural Networks.Metabolites. 2023 Feb 24;13(3):339. doi: 10.3390/metabo13030339. Metabolites. 2023. PMID: 36984779 Free PMC article.
-
Nidogen-2 (NID2) is a Key Factor in Collagen Causing Poor Response to Immunotherapy in Melanoma.Pharmgenomics Pers Med. 2023 Mar 4;16:153-172. doi: 10.2147/PGPM.S399886. eCollection 2023. Pharmgenomics Pers Med. 2023. PMID: 36908806 Free PMC article.
-
Comprehensive analysis of tissue proteomics in patients with papillary thyroid microcarcinoma uncovers the underlying mechanism of lymph node metastasis and its significant sex disparities.Front Oncol. 2022 Aug 29;12:887977. doi: 10.3389/fonc.2022.887977. eCollection 2022. Front Oncol. 2022. PMID: 36106120 Free PMC article.
References
-
- Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide:IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; [accessed on 06/018/2019]. http://globocan.iarc.fr.
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424. - PubMed
-
- Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC) : A phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21. - PubMed
-
- Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
